Department of Nephrology and Kidney Transplantation, Queen Elizabeth Hospital, Birmingham, B15 2WB, United Kingdom.
J Am Soc Nephrol. 2012 Nov;23(11):1891-9. doi: 10.1681/ASN.2012030260. Epub 2012 Oct 11.
The impact of variation within genes responsible for the disposition and metabolism of calcineurin inhibitors (CNIs) on clinical outcomes in kidney transplantation is not well understood. Furthermore, the potential influence of donor, rather than recipient, genotypes on clinical endpoints is unknown. Here, we investigated the associations between donor and recipient gene variants with outcome among 4471 white, CNI-treated kidney transplant recipients. We tested for 52 single-nucleotide polymorphisms (SNPs) across five genes: CYP3A4, CYP3A5, ABCB1 (MDR1; encoding P-glycoprotein), NR1I2 (encoding the pregnane X receptor), and PPIA (encoding cyclophilin). In a discovery cohort of 811 patients from Birmingham, United Kingdom, kidney donor CC genotype at C3435T (rs1045642) within ABCB1, a variant known to alter protein expression, was associated with an increased risk for long-term graft failure compared with non-CC genotype (hazard ratio [HR], 1.69; 95% confidence interval [CI], 1.20-2.40; P=0.003). No other donor or recipient SNPs were associated with graft survival or mortality. We validated this association in 675 donors from Belfast, United Kingdom (HR, 1.68; 95% CI, 1.21-2.32; P=0.002), and in 2985 donors from the Collaborative Transplant Study (HR, 1.84; 95% CI, 1.08-3.13; P=0.006). In conclusion, these data suggest that an ABCB1 variant known to alter protein expression represents an attractive candidate for future study and risk stratification in kidney transplantation.
基因变异对钙调磷酸酶抑制剂(CNIs)处置和代谢的影响,尚不清楚其对肾移植临床结果的影响。此外,供体而不是受体基因型对临床终点的潜在影响尚不清楚。在这里,我们研究了 4471 名白人、接受 CNI 治疗的肾移植受者中供体和受者基因变异与结局之间的关系。我们在五个基因中测试了 52 个单核苷酸多态性(SNP):CYP3A4、CYP3A5、ABCB1(MDR1;编码 P-糖蛋白)、NR1I2(编码孕烷 X 受体)和 PPIA(编码亲环蛋白)。在英国伯明翰的 811 例患者的发现队列中,ABCB1 中的 C3435T(rs1045642)CC 基因型与长期移植物衰竭的风险增加相关,而非 CC 基因型(危险比[HR],1.69;95%置信区间[CI],1.20-2.40;P=0.003)。没有其他供体或受体 SNP 与移植物存活或死亡率相关。我们在英国贝尔法斯特的 675 名供体(HR,1.68;95% CI,1.21-2.32;P=0.002)和协作移植研究的 2985 名供体(HR,1.84;95% CI,1.08-3.13;P=0.006)中验证了这种相关性。总之,这些数据表明,一种已知改变蛋白表达的 ABCB1 变体可能是未来肾移植研究和风险分层的有吸引力的候选物。